Physician profile
William Lim
NPI 1952966103
$5,943.01
in general payments reported to CMS, 2019-2025
20 companies · $3,093 in 2025
The $3,093 reported for 2025 was more than what 96% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $287 · 2023: $1,094 · 2024: $1,470 · 2025: $3,093.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,007 · Travel and Lodging: $1,648.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,007.45 |
| Travel and Lodging | $1,648.43 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Philips North America LLC | $1,307.78 | 2025 | Igt Devices Undivided |
| Inari Medical, INC. | $943.76 | 2023-2024 | Ct Thrombectomy System Kit, Flowtriever Catheter, S |
| Abiomed | $773.19 | 2025 | |
| Boston Scientific Corporation | $507.89 | 2023-2025 | General - Vascular Access, Watchman Flx, Watchman Access System |
| Medtronic, INC. | $437.93 | 2022-2025 | Corevalve Evolut R, Azure Xt Dr Mri Surescan, Cobalt Dr Mri Surescan |
| Penumbra, INC. | $363.85 | 2024-2025 | Indigo System |
| Pfizer INC. | $314.27 | 2023-2024 | |
| Angiodynamics, INC. | $184.46 | 2023-2024 | Angiovac, Alphavac |
| Alnylam Pharmaceuticals INC. | $168.24 | 2023-2025 | Amvuttra, Onpattro |
| Merck Sharp & Dohme LLC | $134.62 | 2023-2024 | Verquvo |
| Astrazeneca Pharmaceuticals LP | $132.50 | 2025 | Wainua |
| Boehringer Ingelheim Pharmaceuticals, INC. | $127.78 | 2023 | Jardiance |
| Lexicon Pharmaceuticals, INC. | $124.74 | 2024 | Inpefa |
| Novo Nordisk INC | $124.41 | 2022 | |
| Baxter Healthcare | $118.44 | 2025 | Hillrom - Cardiac Ambulatory Monitor |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $79.20 | 2022-2023 | Camzyos |
| Kiniksa Pharmaceuticals, LTD. | $37.48 | 2022-2023 | Arcalyst |
| Janssen Pharmaceuticals, INC | $23.08 | 2024 | Xarelto |
| Bayer Healthcare Pharmaceuticals INC. | $22.10 | 2024 | |
| Daiichi Sankyo INC. | $17.29 | 2023 | Injectafer |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw William Lim listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.